Is This Medical-Device-Making Dividend Aristocrat a Buy?
The two most telling indications of a quality dividend stock are earnings that consistently increase and dividends that grow along with that growing bottom line. Medtronic (NYSE: MDT) meets both of these criteria, and the S&P 500 component has raised its payout annually for 44 consecutive years, handily qualifying it for the status of Dividend Aristocrat.
But is the stock a buy at its current price?
Let's take a look at Medtronic's solid operating results for the start of its fiscal 2022 (which will end in April), its balance sheet, and its valuation to answer this question.
Source Fool.com
